ESMO 2023: Updates in Genitourinary Cancers

home / post-conference-perspectives / esmo-2023-updates-in-genitourinary-cancers

Siamak Daneshmand, MD, explores genitourinary cancer updates presented at ESMO 2023.

Video 1 - "Biomarkers and Molecular/ Genomic Testing in Genitourinary Cancers"

EP. 1: Biomarkers and Molecular/ Genomic Testing in Genitourinary Cancers

November 27th 2023

Siamak Daneshmand, MD, explores unmet needs in the bladder cancer treatment landscape at ESMO 2023.

Watch

Video 2 - "Bladder Cancer with FGFR Alterations: THOR-2 Cohort 1 Study at ESMO 2023"

EP. 2: Bladder Cancer with FGFR Alterations: THOR-2 Cohort 1 Study at ESMO 2023

November 27th 2023

An examination of data presented at ESMO 2023 from cohort 1 of the THOR-2 study of high-risk non–muscle invasive bladder cancer (HR NMIBC) with FGFR alterations.

Watch

Video 3 - "Overview of BCG-Unresponsive Bladder Cancer Treatments Landscape"

EP. 3: Overview of BCG-Unresponsive Bladder Cancer Treatments Landscape

November 27th 2023

Discussion on current and future treatments for BCG-unresponsive HR NMIBC presented at ESMO 2023.

Watch

Siamak Daneshmand, MD, discusses the results of SunRISe-1 study of TAR-200, an intravesical drug delivery system, in patients with BCG-unresponsive HR NMIBC from ESMO 2023.

EP. 4: ESMO 2023 Insights: SunRISe-1 Study of TAR-200 in BCG-Unresponsive Bladder Cancer

December 11th 2023

Siamak Daneshmand, MD, discusses the results of SunRISe-1 study of TAR-200, an intravesical drug delivery system, in patients with BCG-unresponsive HR NMIBC from ESMO 2023.

Watch

Video 5 - "Key Highlights from EV-302 Study at ESMO 2023"

EP. 5: Key Highlights from EV-302 Study at ESMO 2023

December 11th 2023

Expert insight into the data presented at ESMO 2023 on the EV-302 study of enfortumab vedotin and pembrolizumab in the management of locally advanced or metastatic urothelial carcinoma.

Watch